close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MiNK Therapeutics, Inc. - Common Stock (NQ:INKT)

12.75 -0.47 (-3.56%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MiNK Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
Presentation will feature the ongoing Phase 2 study of agenT-797 in refractory gastric cancer 
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update
From MiNK Therapeutics
Via GlobeNewswire
News headline image
Examining the Future: MiNK Therapeutics's Earnings Outlook ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 14, 2024 ↗
 
Via Benzinga
News headline image
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
From MiNK Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference
From MiNK Therapeutics
Via GlobeNewswire
News headline image
INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q2 2024 ↗
INKT stock results show that MiNK Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
MiNK Reports Second Quarter 2024 Results and Business Update
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
From MiNK Therapeutics
Via GlobeNewswire
News headline image
INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q1 2024 ↗
INKT stock results show that MiNK Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
MiNK Reports First Quarter 2024 Results
From MiNK Therapeutics
Via GlobeNewswire
News headline image
Why MiNK Therapeutics Stock Is Up 11% Monday ↗
MiNK Therapeutics shares are trading higher Monday after the clinical-stage biopharmaceutical company announced private placement financing of $5.8 million. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
From MiNK Therapeutics
Via GlobeNewswire
News headline image
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
INKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023 ↗
INKT stock results show that MiNK Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
MiNK Reports Fourth Quarter and Year-End 2023 Results
From MiNK Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today